Taxane Chemotherapy for Metastatic Breast Cancer
Author Information
Author(s): Ghersi D, Wilcken N, Simes R J
Primary Institution: NHMRC Clinical Trials Centre, University of Sydney
Hypothesis
Do taxane-containing chemotherapy regimens improve survival compared to non-taxane regimens in women with metastatic breast cancer?
Conclusion
Taxane-containing regimens improve overall survival in women with metastatic breast cancer compared to some non-taxane regimens.
Supporting Evidence
- Taxane-containing regimens showed a significant difference in overall survival (HR 0.93, p=0.05).
- Taxanes improved time to progression (HR 0.92, p=0.02).
- Overall response rates were significantly better with taxanes (OR 1.34, p<0.0001).
Takeaway
This study found that using taxane drugs helps women with advanced breast cancer live longer compared to some other treatments.
Methodology
A systematic review and meta-analysis of randomized trials comparing taxane-containing regimens with non-taxane regimens.
Potential Biases
Quality of randomization was often unclear, which may introduce bias.
Limitations
Not all trials reported on all outcomes, and some had immature data.
Participant Demographics
Women with metastatic breast cancer, with no age restrictions.
Statistical Information
P-Value
0.05
Confidence Interval
0.86–1.00
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website